1. Harjola VP, et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Failure 2010;12:239–48.
2. Mebazaa A, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010;31:832–41.
3. Gheorghiade M, Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. et al. JAMA 2006;296:2217–26.
4. Adams KF, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209–16.
5. Metra M, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196–206.
6. Metra M, Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. et al. Eur J Heart Failure 2010;12:499–507.
7. Teerlink JR, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29–39.
8. Ponikowski P, et al. Design of the RELAXin in acute heart failure study. Am Heart J 2012;163:149–55.